ÔçÒÒŮѸÀ×

    • <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      
    

    

      Halozyme Therapeutics Inc.
      Halozyme Therapeutics Inc.
      HALO
      Market Cap$8.56B
       Close$
      
      
      
      
      Compare to Similar Companies
      P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
      Halozyme Therapeutics Inc.Halozyme Therapeutics Inc.15.9-167%8.24.2
      $62.00
      Target Price by Analysts
      15.5% downsideHalozyme Therapeutics Target Price DetailsTarget Price
      $58.50
      Current Fair Value
      20.3% downside
      Overvalued by 20.3% based on the discounted cash flow analysis.
      Share Statistics
      Market cap$8.56 Billion
      Enterprise Value$9.89 Billion 
      Dividend Yield$- (-)
      Earnings per Share$3.5 
      Beta1.17
      Outstanding Shares121,343,000
      Return
      Return on Equity-
      Return on Assets-
      Return on Invested Capital-
      Valuation & Multiples
      P/E Ratio15.93
      PEG20.65
      Price to Sales8.16
      Price to Book Ratio36.7
      Enterprise Value to Revenue8.39
      Enterprise Value to EBIT14.05
      Enterprise Value to Net Income17
      Total Debt to Enterprise0.14
      Debt to Equity4.19
      Revenue Sources
      No data
      Insider Trades
      ESG Score
      No data
      About Halozyme Therapeutics Inc.
      CEO: Helen Torley 
      
      
      


    
      
  
      
    

    
  
      

      

    
      
  To improve your user experience we use
  cookies.
  

      

    
  
  
      
  
      

  
  

  

  
  

  
HoMEÔçÒÒŮѸÀ×